MNG242
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.569
- ANGIOGENESIS+0.515
- KRAS_SIGNALING_UP+0.415
- PANCREAS_BETA_CELLS+0.383
- TNFA_SIGNALING_VIA_NFKB+0.378
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.341
- HYPOXIA+0.330
- KRAS_SIGNALING_DN+0.325
- COAGULATION+0.314
- ESTROGEN_RESPONSE_LATE+0.308
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.496
- DNA_REPAIR-0.396
- E2F_TARGETS-0.330
- PI3K_AKT_MTOR_SIGNALING-0.322
- MYC_TARGETS_V2-0.313
- MYC_TARGETS_V1-0.290
- G2M_CHECKPOINT-0.276
- INTERFERON_GAMMA_RESPONSE-0.275
- MITOTIC_SPINDLE-0.259
- UNFOLDED_PROTEIN_RESPONSE-0.251
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG789 | — | — | 0.882 |
| 2 | R251 | — | — | 0.854 |
| 3 | MNG924 | — | — | 0.848 |
| 4 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.839 |
| 5 | MNG931 | — | — | 0.838 |
| 6 | MNG113 | — | — | 0.838 |
| 7 | TCGA-KQ-A41S-01A-12R-A33J-07 | — | — | 0.832 |
| 8 | SRR1413522 | GTEX | — | 0.832 |
| 9 | MNG128 | — | — | 0.830 |
| 10 | MBCproject_0031_T1_RNA | — | A | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.569 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.515 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.415 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.383 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.378 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.341 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.325 | Remibrutinib | — uncovered |
| COAGULATION | 0.314 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.308 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.281 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.261 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.243 | Inavolisib | — uncovered |
| MYOGENESIS | 0.236 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.207 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.206 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.202 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.179 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.141 | Inavolisib | — uncovered |